TECX Tectonic Therapeutic, Inc.

CIK 0001681087 38 ready 8-Ks latest June 10, 2026, 5:08 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 38

Latest filing June 10, 2026, 5:08 PM ET

Top materiality 1.00

Event mix other_material ×12 · earnings ×10 · m_and_a ×8

Sentiment 16 pos · 2 neg · 20 neu

Latest earnings reported 2026-Q1

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for TECX

Highest-materiality recent filing

Tectonic Therapeutic completes merger with AVROBIO, begins trading as TECX

June 20, 2024, 7:59 PM ET M&A materiality 1.00 neutral item 2.01 item 1.01 item 9.01 item 5.02 item 4.01 item 2.02 item 3.02 item 3.03 item 5.01 item 5.03 item 5.06 item 8.01 ◈ executive_change ×12◈ M&A Transactions

Merger completed on June 20, 2024; AVROBIO merged into Tectonic, which survived as a wholly owned subsidiary.
AVROBIO effected a 1-for-12 reverse stock split and changed its name to Tectonic Therapeutic, Inc.

Read filing →

June 10, 2026, 5:08 PM ET other material materiality 0.70 positive item 5.07 item 8.01 item 9.01 ◈ Shareholder Votes ×3

Tectonic completes enrollment in Phase 2 TX45 trial for PH-HFpEF; topline data expected early Q1 2027

APEX trial enrolled 191 patients across 14 countries; 72% (137 pts) in enriched CpcPH subset (PVR > 3 WU).
May 7, 2026, 7:59 PM ET earnings materiality 0.60 negative item 2.02 item 9.01 ◈ Earnings Releases

Tectonic Therapeutic Q1 net loss $25.2M; TX45 APEX Phase 2 enrollment near complete

Net loss $25.2M in Q1 2026 vs. $15.9M in Q1 2025; R&D expense $20.9M (up $7.9M YoY).
February 26, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Tectonic Q4 net loss $19.2M; TX45 Phase 1b positive, TX2100 Phase 1a started

Q4 net loss $19.2M (vs $12.4M YoY); R&D expenses $16.3M on advancing pipeline.
November 6, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Tectonic Q3 net loss $19M; positive TX45 Phase 1b data in PH-HFrEF

Net loss of $19.0M in Q3 2025 vs $17.7M in Q3 2024; R&D expenses $16.9M.
October 30, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Tectonic Therapeutic reports positive Phase 1b Part B data for TX45 in PH-HFrEF

Single dose of TX45 improved left heart function and pulmonary hemodynamics: PCWP -29.2%, CO +17.3%, mPAP -19.3%, TPR -29.2% mean change.
August 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Tectonic Therapeutic Q2 net loss $20M; cash $287.4M; TX45 PH-ILD Phase 2 planned 2026

Net loss of $20.0M in Q2 2025 vs $12.7M in Q2 2024; R&D expenses rose to $17.2M from $7.1M.
May 19, 2025, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Tectonic TX45 Phase 1b in PH-HFpEF shows 19% PCWP reduction, sustained 29-day effects

Single IV dose of TX45 reduced PCWP by 19.0% [95% CI, -26.1% to -11.9%] in 19-patient cohort.
May 8, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01

Tectonic Q1 net loss $15.9M; cash $306M; TX45 Phase 1b shows PCWP reduction 17.9%

Net loss of $15.9M for Q1 2025 vs $15.2M in Q1 2024; R&D expenses $13.0M, G&A $5.3M.
March 20, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Tectonic reports Q4 2024 net loss $12.4M; positive TX45 Phase 1b interim results

TX45 Phase 1b Part A reduced PCWP by 17.9% in PH-HFpEF and PVR >30% in CpcPH subgroup.
February 3, 2025, 6:59 PM ET other material materiality 0.70 neutral item 1.01 item 3.02 item 7.01 item 9.01

Tectonic raises $185M via PIPE of 3.69M shares to fund clinical pipeline

Gross proceeds ~$185M; 3,689,465 shares at $50.00 (fund investors) and $54.14 (officer/directors).
January 30, 2025, 6:59 PM ET other material materiality 0.80 positive item 7.01 item 8.01 item 9.01

TX45 Phase 1b data show 17.9% PCWP reduction in PH-HFpEF; >30% PVR cut in CpcPH subgroup

TX45 achieved 17.9% reduction in PCWP (overall population) and >30% reduction in PVR in CpcPH patients.
November 7, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Tectonic Therapeutic Q3 net loss $17.7M; TX45 Phase 1b enrollment ahead; new HHT candidate TX2100

Net loss of $17.7M for Q3 2024 vs $10.1M a year ago; R&D spend $14.3M (up from $8.1M) on TX45 trials.
September 19, 2024, 7:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Tectonic reports positive Phase 1a data for TX45; Phase 2 doses selected, Phase 1b dose escalated

Phase 1a: TX45 well-tolerated, no immunogenicity, robust PK/PD; Phase 2 doses set at 300 mg SC monthly or every other week.
August 14, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Tectonic reports Q2 net loss $12.7M; cash $185.1M; TX45 Phase 2 trial open

Net loss of $12.7M for Q2 2024 vs $10.5M in Q2 2023; R&D expenses $7.1M.
July 30, 2024, 7:59 PM ET regulatory materiality 0.75 positive item 7.01 item 8.01 item 9.01

Tectonic Therapeutic receives FDA IND clearance for lead program TX45 in PH-HFpEF

FDA cleared IND for TX45 (Fc-relaxin fusion) for Group 2 PH due to HFpEF, a condition with no approved therapy affecting >600K US patients.
June 26, 2024, 7:59 PM ET other material materiality 0.70 neutral item 7.01 item 8.01 item 9.01

Tectonic Therapeutics details TX45 Phase 2 trial design for Group 2 PH-HFpEF

Phase 2 randomized, placebo-controlled, double-blind trial to start H2 2024 globally (US, Europe, Eastern Europe, Australia).
June 20, 2024, 7:59 PM ET M&A materiality 1.00 neutral item 2.01 item 1.01 item 9.01 item 5.02 item 4.01 item 2.02 item 3.02 item 3.03 item 5.01 item 5.03 item 5.06 item 8.01 ◈ executive_change ×12◈ M&A Transactions

Tectonic Therapeutic completes merger with AVROBIO, begins trading as TECX

Merger completed on June 20, 2024; AVROBIO merged into Tectonic, which survived as a wholly owned subsidiary.
June 18, 2024, 7:59 PM ET M&A materiality 0.60 neutral item 8.01

AVROBIO merger with Tectonic delayed to June 20; 1-for-12 reverse split effective June 20; new ticker TECX

Merger closing postponed from June 18 to around June 20, 2024.
June 14, 2024, 7:59 PM ET M&A materiality 0.85 neutral item 8.01

AVROBIO approves 1-for-12 reverse stock split; merger with Tectonic to close June 18

Reverse stock split at 1-for-12 ratio effective 4:00 pm ET on June 18, 2024.
June 11, 2024, 7:59 PM ET M&A materiality 0.75 positive item 5.07

AVROBIO stockholders approve all proposals for merger with Tectonic Therapeutic

Stock issuance and change-of-control proposal passed: 30,233,557 For, 1,899,576 Against.
June 4, 2024, 7:59 PM ET other material materiality 0.60 neutral item 8.01

AVROBIO voluntarily supplements merger disclosures as three shareholder suits challenge deal

Three shareholder lawsuits filed in NY state and federal court allege Registration Statement omissions; seek to enjoin merger.
January 30, 2024, 6:59 PM ET M&A materiality 0.90 positive item 1.01 item 5.01 item 5.02 item 7.01 item 9.01 ◈ Material Agreements

AVROBIO to merge with Tectonic in all-stock deal; $130.7M private financing; combined company targets GPCRs

Pre-merger AVRO holders expected to own ~22.3%; Tectonic holders ~40.2%; financing investors ~37.5% of combined firm.
January 30, 2024, 6:59 PM ET M&A materiality 0.75 neutral item 7.01 item 9.01

AVROBIO enters into definitive merger with Tectonic Therapeutic

AVRO (AVRO) signs merger agreement with Tectonic; Merger Sub will merge into Tectonic, making it a wholly-owned subsidiary.
July 12, 2023, 7:59 PM ET other material materiality 0.75 negative item 2.05 item 7.01 item 9.01 ◈ Restructurings & Charges

AVROBIO halts gene therapy programs, cuts 50% workforce, explores strategic alternatives

Board approved halting all program development; workforce reduction of ~50% expected by end of July 2023.
June 12, 2023, 7:59 PM ET M&A materiality 0.80 positive item 1.02 item 2.01 item 5.02 item 7.01 item 9.01 ◈ M&A Transactions

AVROBIO completes $87.5M sale of cystinosis gene therapy program to Novartis; cash runway extended to Q4 2024

Sale closed June 9, 2023 for $87.5M cash; proceeds expected to extend cash runway into Q4 2024.
May 22, 2023, 7:59 PM ET M&A materiality 0.85 positive item 1.01 item 2.05 item 7.01 item 9.01 ◈ Material Agreements◈ Restructurings & Charges

AVROBIO sells cystinosis gene therapy program to Novartis for $87.5M cash

Sale of AVR-RD-04 to Novartis for $87.5M cash at closing; proceeds to extend cash runway into Q4 2024.
May 18, 2023, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 9.01

AVROBIO reports positive Phase 1/2 gene therapy data for cystinosis; all patients off oral cysteamine up to 36 months

All six patients remain off oral cysteamine up to 36 months post gene therapy.
May 11, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

AVROBIO Q1 net loss $25.0M, cash $72.3M; appoints interim CEO; GD3 trial on track

Net loss of $25.0M for Q1 2023 vs $29.8M in Q1 2022; R&D expenses $17.3M, G&A $7.9M.
May 1, 2023, 7:59 PM ET leadership materiality 0.70 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

AVROBIO CEO Geoff MacKay resigns; CFO Erik Ostrowski named interim CEO

CEO Geoff MacKay resigns effective May 1, 2023, to join an early-stage company; no disagreement with the company.
March 23, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

AVROBIO reports Q4 net loss $25.0M, full-year 2022 loss $105.9M; cash $92.6M

Net loss of $25.0M in Q4 2022 vs $28.2M in Q4 2021; full year loss $105.9M vs $119.1M.